Articles On Pharmaust (ASX:PAA)

PharmAust (ASX:PAA) says it will undertake an interim analysis of preliminary biomarkers and efficacy markers on completion of dosing of the last patient of Cohort 2 in its motor neurone disease trial of Monepantel.

Protection of PharmAust’s intellectual property has hit a milestone with the impending grant of a key patent relating to the use of Monepantel in conjunction with other drugs to treat cancer. The European Patent Office has issued a Notice o...

PharmAust (PAA) is set to secure a European patent for the use of its Monepantel (MPL) product in combination with other drugs to treat cancer The company has been issued a “notice to grant” from the European Patent Office for pharmaceut...

PharmAust (PAA) doses the first patient in the second cohort of its motor neurone disease (MND) trial for its monepantel (MPL) product The company’s testing showed MPL was “well-tolerated” by all MND patients at the first dosing level, l...

PharmAust has dosed the first patient of the second cohort in its Phase 1/2 Motor Neurone Disease (MND) clinical trial mere weeks after securing approval to proceed with an escalated dose. The patient will receive 4mg/kg of the company’s le...

PharmAust has set up veterinary trial centres in Australia, New Zealand and the United States to evaluate the anti-cancer benefit of Monepantel (MPL) tablets in dogs diagnosed with untreated B-cell lymphoma. Thirty-five dogs have so far bee...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

PharmAust (ASX:PAA) has announced that the Trial Safety Committee has approved an escalation of the Monepantel dose in a trial in patients with Motor Neurone Disease.

PharmAust (PAA) has received the green light from the trial safety committee to increase the tablet dosage in its motor neurone disease study The company reported no safety issues or serious adverse events found during its study, as a...

The ASX will open flattish despite a selloff on Wall Street US jobless claims fell as the job market remains hot US hits its debt ceiling today   Aussie shares are set to open slightly higher on Friday despite a selloff in New York overni...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

PharmAust (ASX:PAA) has announced that it had completed its first cohort of six patients in the Phase 1/2 clinical trial of its lead drug candidate monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis.

PharmAust (PAA) doses the first cohort of patients in its Phase 1/2 clinical trial of lead drug candidate monepantel (MPL) At the first dosing level, the MPL tablets were well tolerated by all six patients, who each elected to continue o...

PharmAust is moving on to the next stage of its Phase 1/2 Motor Neurone Disease (MND) trial after its lead drug monepantel was found to be well tolerated by patients at the first dosing level. Further highlighting the success of the treatme...

Stock Insiders is a podcast series focussed on investing hosted by renowned business journalist Oriel Morrison.  In this episode Oriel talks to Anusha Aubert, head of investor relations at PharmAust (ASX:PAA). The company is a clinical-stag...

Leading Australian biotech company PharmAust has received recognition for its innovative clinical research, backed by a Research and Development Tax Incentive (RDTI) for the 2022 tax year. The Australian Taxation Office has approved PharmAu...

PharmAust (PAA) completes enrolment of the first cohort of six motor neurone disease (MND) patientsThe clinical study aims to determine the tolerability, safety and efficacy of oral MPL in individuals living with MNDThe final patient for th...

PharmAust (ASX: PAA) has enrolled the first patient cohort for its phase 1/2 clinical trial testing its lead drug candidate monepantel (MPL) in sufferers of motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). The first cohort com...

Owners of dogs participating in the MPL trial said they have seen an increase in the quality of life of their pets.   An estimated 6 million dogs are diagnosed with cancer each year in the US compared to 1.7 million humans. Many of the most...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements. To save you the trouble of trudging through it all, we’ve wrapped up the highlights from some of the reports that caug...

Clinical stage biotechnology company PharmAust’s (ASX: PAA) September quarter was highlighted by the commencement of its Motor Neurone Disease (MND) trial, recruiting its first four patients, as additional patients undergo screening to beco...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Australian biotechnology company PharmAust (ASX:PAA) has announced that the first patient has been dosed in its Phase 1/2 clinical trial testing the effects of its monepantel in people living with motor neurone disease.

PharmAust (PAA) doses its first patient in a phase one/two trial to test the effects of its monepantel drug in individuals living with motor neurone diseaseThe trial looks to test the safety and tolerability of MPL in patients living with t...

The Phase 1/2 trial will study the safety and efficacy of PharmAust’s lead drug monepantel in treating people with MDS or Lou Gehrig’s disease. Clinical stage biotech company PharmAust (ASX:PAA) has made the first clinical step towards prog...

PharmAust (ASX: PAA) has dosed the first patient of its phase 1/2 trial evaluating its lead drug monepantel (MPL) in people suffering from motor neurone disease (MND). The company has also secured ethics approval to make “small amendments”...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has recruited the first canine with B-cell lymphoma to its Phase 2 trial centre in the US to assess the efficacy of treatment using lead drug monepantel (MPL). The medical oncology t...

Ongoing Phase 2 results from the study of Monepantel to treat canines with B cell lymphoma have been encouraging. Now PharmAust will expedite the study by taking it to the US. PharmAust (ASX:PAA) has recruited the first pet dog with B cell...

PharmAust (PAA) recruits the first pet dog with B cell lymphoma for its US canine phase two trialThe trial looks to assess the efficacy of PAA’s Monepantel (MPL) treatment in up to ten dogs with untreated B cell lymphomaThe dog will be requ...

PharmAust’s ongoing trials on canine cancer have returned very encouraging results. The company has expanded the study to NZ and the US. PharmAust (ASX:PAA) has announced significant progress in the canine cancer trials of its primary drug...

Biotech company PharmAust (PAA) reports “significant progress” on its canine cancer trials The company has found that the combination of its Monepantel (MPL) drug candidate and the standard of care can more than double the life expectancy...

The latest results from PharmAust’s (ASX: PAA) canine trials have revealed that a combination of the company’s lead drug candidate monepantel (MPL) and standard of care can more than double the life expectancy of dogs with cancer. In additi...

PharmAust (ASX: PAA) could soon open the door to billion-dollar drug success opportunities after recent positive developments through testing and trials on its primary lead drug candidate monepantel (MPL). The Perth-based clinical stage bio...

PharmAust’s clinical trials in canine cancers, human cancers, Covid-19 and MND/ASL could lead to multi-billion dollar opportunities, according to broker JP Equity. Leading broker JP Equity Partners believes that clinical stage biotech Pharm...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

Perth-based biotech PharmAust (ASX: PAA) has reported a June quarter heavily focused on the effects of its primary drug candidate monepantel on patients with motor neurone disease. For the three months to end June, the company reported comp...

PharmAust subsidiary Epichem’s pilot agreement with Shell Australia was made possible by NERA, a non-profit that matches SMEs with industry giants. PharmAust’s (ASX:PAA) wholly owned subsidiary, Epichem, has secured a recycling pilot progra...

Clinical-stage biotechnology company PharmAust (ASX: PAA) wholly-owned subsidiary Epichem has been awarded a $45,200 grant from National Energy Resources Australia (NERA) to advance a carbon-neutral solution for recycling plastic waste. The...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

With the expansion of canine trials of its Monepantel treatment for B-cell lymphoma to the US in May, PharmAust is now presenting its findings to an audience of peers. Dr Catherine Chan, the vet oncologist at the Jindalee Veterinary Hospita...

FightMND’s annual Big Freeze event will be held during the AFL match between Collingwood and Melbourne at the MCG on June 13th. Motor neurone disease (MND), sometimes called amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, is a...

The appointment of former Novartis exec Fiona Milner will provide PharmAust’s subsidiary Epichem the leadership it needs to take the company to the next stage. PharmAust’s (ASX:PAA) wholly owned subsidiary, Epichem, has bolstered its team f...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has appointed industry executive Fiona Milner as general manager of its Perth-based subsidiary Epichem, effective end of June. Ms Milner has 25 years’ experience working for multinat...

PharmAust (ASX:PAA) is launching a Phase 1 clinical trial of monepantel for the treatment of motor neuron disease or Amyotrophic Lateral Sclerosis.

Biotechnology company PharmAust (ASX: PAA) has updated the market on its range of clinical trials, led by developments relating to lead drug candidate monepantel. The company’s manufacturing program includes production of the drug’s active...

PharmAust (PAA) is facing delays for its phase one COVID-19 trial as it works to find a suitable site to achieve patient recruitment numbers The trial is aiming to use its Monepantel (MPL) tablets to monitor the anti-viral effects of the d...